RT Journal Article
SR Electronic
T1 Effects of SARS-CoV-2 P.1 introduction and the impact of COVID-19 vaccination on the epidemiological landscape of São José Do Rio Preto, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.28.21261228
DO 10.1101/2021.07.28.21261228
A1 Banho, Cecília Artico
A1 Sacchetto, Lívia
A1 Campos, Guilherme Rodrigues Fernandes
A1 Bittar, Cíntia
A1 Possebon, Fábio Sossai
A1 Ullmann, Leila Sabrina
A1 Marques, Beatriz de Carvalho
A1 da Silva, Gislaine Ceslestino Dutra
A1 Moraes, Marília Mazzi
A1 Parra, Maisa Carla Pereira
A1 Negri, Andreia Francesli
A1 Boldrin, Ana Carolina
A1 Barcelos, Michela Dias
A1 dos Santos, Thayza M. I. L.
A1 Milhim, Bruno H. G. A.
A1 da Rocha, Leonardo Cecílio
A1 Dourado, Fernanda Simões
A1 dos Santos, Andresa Lopes
A1 Ciconi, Victoria Bernardi
A1 Patuto, Caio
A1 Versiani, Alice Freitas
A1 da Silva, Rafael Alves
A1 Lobl, Edoardo Estevam de Oliveira
A1 Hernandes, Victor Miranda
A1 Zini, Nathalia
A1 Pacca, Carolina Colombelli
A1 Estofolete, Cássia Fernanda
A1 Ferreira, Helena Lage
A1 Rahal, Paula
A1 Araújo, João Pessoa
A1 Cohen, Jamie A.
A1 Kerr, Cliff C.
A1 Althouse, Benjamin M.
A1 Vasilakis, Nikos
A1 Nogueira, Mauricio Lacerda
YR 2021
UL http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261228.abstract
AB The emergence of the new Brazilian variant of concern, P.1 lineage (Gamma), raised concern about its impact on the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. Using 272 whole-genome sequences combined with epidemiological data, we showed that P.1 introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of eight circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection. Our findings support that the P.1 variant is associated with an increase in mortality risk and severity of COVID-19 cases in younger aged groups, which corresponds to the unvaccinated population at the time. Moreover, our data highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge Rede Corona-Omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP= 01.20.0029.000462/20, CNPq= 404096/2020-4, CNPq fellowship= 382032/2020-9 to C.A.B), FINEP (Grant #01180149-00), Multiuser Laboratory (LMU) at Sao Jose do Rio Preto School of Medicine (FAMERP), Brazil, for their support with the use of equipments (MiSeqTM, Illumina Inc, USA). Funding support is acknowledged from FAPESP-COVID Program (Grant #2020/04836-0 to MLN), JBS Support for COVID-19 Response Research, FAPESP fellowships (2020/07419-0 to GRFC), Fundacao Butantan (FAPESP Grant #2020/10127), Capes (Grant #0001), and partly by the Centers for Research in Emerging Infectious Diseases (CREID), The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) grant 1U01AI151807 awarded to NV by the National Institutes of Health (NIH/USA). MLN, PR, JPAJ are CNPq Research Fellows. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of Faculdade de Medicina de Sao Jose do Rio Preto Institutional Review Board (protocol number: CAE# 31588920.0.0000.5415)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability All SARS-CoV-2 genomes generated and analyzed in this study are available at EpiCoV database in GISAID (https://www.gisaid.org), and their respective access number are available at Supplementary Material. https://www.gisaid.org